CNX Therapeutics has taken over the global rights to Sativex (nabiximols) from Jazz Pharmaceuticals. This deal, finalized on October 31, 2025, includes all the necessary permissions, business partnerships, and production agreements. Sativex is a medicine approved in the European Union, the United Kingdom, and other countries. It is used for adults with moderate to severe muscle stiffness caused by multiple sclerosis (MS) who haven’t found relief from other treatments and have shown improvement during an initial trial. Guy Clark, the CEO of CNX Therapeutics, said, ‘This acquisition strengthens our role in providing special nervous system medicines across Europe. Sativex, the first plant-derived cannabis-based medicine approved by regulators, is a big step in our plan to grow by focusing on areas where we can make a real difference. We are committed to ensuring a steady supply and long-term support for patients and healthcare professionals.’ Jazz Pharmaceuticals will help CNX through a transition period to ensure a smooth transfer. Ben Moore, Vice President of Corporate Development at CNX Therapeutics, added, ‘Our experience in nervous system treatments made this acquisition a good fit as we build our European specialty medicine portfolio. We are focused on making sure patients who need this treatment can continue to access it without interruption.’ This deal is an important move in CNX Therapeutics’ plan to expand and improve access to essential medicines for people with long-term neurological conditions.